AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting. The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and twelve months after, in a real-life setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent zarejestrowany w bazie danych PLATON
- •Wiek 18 lat lub więcej
- •Pacjent z białaczką limfocytową wcześniej nieleczony, który otrzymuje acalabrutinib
- •Zgoda na wykorzystanie danych zdrowotnych do celów badawczych
- •Pacjenci, którzy przerwali leczenie przed 12 miesiącami również mogą uczestniczyć
✗ Disqualifies
- •Kobiety w ciąży
- •Pacjenci pozostający pod opieką sądową
- •Pacjenci powyżej 18 lat niezdolni do wyrażenia sprzeciwu
- •Pacjenci, którzy wcześniej otrzymywali inne leczenie białaczki limfocytowej
Simplified criteria — AI translation
Trial details
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Locations (1)
Research Site
Saint-Affrique, France
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.